Investor Relations

Company Description

News

Financial Reports

Financial Calendar

Presentations

The Share

New Issues

Corporate Governance

IR Contact

Dignitana AB Publishes Q1 2022 Interim Report

Solid growth trend continues at 21 percent

Financial highlights Q1 2022

  • Net sales amounted to 15.9 MSEK (13.2), an increase of 21 percent over the same period in 2021.
  • Operating result amounted to -6.1 MSEK (-7.1).

  • Net result after financial items amounted to -6.5 MSEK (-7.7).

  • Earnings per share were -0,10 SEK (-0,12).

  • Cash Balance amounted to 11.3 MSEK (44.4).

  • Average Daily Treatment Revenue (ADTR)* was 179 TSEK (130), an increase of 38 percent over the same period in 2021.

Significant events during the period

  • The Board appointed Catarina Mård Löwenadler as Chief Executive Officer of Dignitana AB to begin on 20 May 2022.

  • The company named Alf Christensson as Interim Chief Financial Officer and he assumed the role 1 March 2022.

Business highlights during the period

  • On 9 March 2022 Dignitana Chief Executive Officer William Cronin addressed the Stockholm Corporate Finance Life Science Capital Markets Days, providing an update on the company’s strategic growth and discussing current reimbursement initiatives.
  • In early March Dignitana sponsored the More than Pink Walk in Orlando, Florida,continuing the partnership with Susan G Komen® we initiated in 2020 to increase awareness of scalp cooling.

Significant events after the period

  • Dignitana published the 2021 Annual Report in April.

  • The company appointed Ulf Jönsson as Chief Financial Officer to begin 1 July 2022.

Key Figures

DIGNITANA GROUP

Q1 2022

Q1 2021

Full Year 2021
Net sales, TSEK  15 864  13 165  57 073
Total revenues, TSEK  16 710  14 157  62 376
Net profit after financial items, TSEK -6 508 -7 664 -43 076
Cash and bank balances, TSEK 11 311 44 366  14 501
Earnings per share before and after dilution, SEK -0,10 -0,12 -0,66
Average Daily Treatment Revenue*, TSEK 179 130 147

* ADTR includes pay-per-treatment revenue from patients and facilities. Does not include lease revenue or disposable sales.

All financial reports are available at www.dignitana.com/investor-relations/financial-reports/


 


This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 19-05-2022 08:30 CET.

For More Information Contact 

Melissa Bourestom, Chief Communications Officer,  melissa.bourestom@dignitana.com  +1 469-518-5031

About Dignitana

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001.  Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States.  Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB +46 8 121 576 90, certifiedadviser@redeye.se. Learn more at www.dignitana.com or www.dignicap.com.